Company profile: Foresight Diagnostics
1.1 - Company Overview
Company description
- Provider of liquid biopsy-based cancer detection and monitoring solutions leveraging patient-specific phased variants, including Foresight CLARITY MRD assays for lymphoma and solid tumors; the PhasED-Seq high-sensitivity ctDNA test; MRD-driven clinical trials; a ctDNA research assay to quantify and monitor disease burden; and customizable SNV and CNV genotyping.
Products and services
- PhasED-Seq: A validated liquid-biopsy test for MRD that leverages phased variants to sensitively detect ctDNA across cancers including B-cell malignancies, lung cancer, and breast cancer
- Foresight CLARITY for Lymphoma: An off-the-shelf MRD assay detecting extremely low ctDNA in plasma using patient-specific phased variants, used for various B-cell malignancies
- Foresight CLARITY for Solid Tumors: A tumor-informed MRD assay achieving high sensitivity via patient-specific phased variants identified with whole-genome sequencing, used for translational research in solid tumors
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Foresight Diagnostics
Saladax Biomedical
HQ: United States
Website
- Description: Provider of therapeutic drug monitoring assays and services for psychiatry and oncology, including MyCare Psychiatry for rapid blood level measurement of antipsychotic drugs and MyCare Oncology for rapid therapeutic drug level testing to assist treatment plans; also offers application sheets for measuring clozapine, olanzapine, quetiapine, and total risperidone using Beckman Coulter systems.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Saladax Biomedical company profile →
GeneCentric Therapeutics
HQ: United States
Website
- Description: Provider of molecular diagnostic tests and RNA-based informatics for oncology, including rT(I)ME Explorer for therapy-selective gene signatures, PurIST for PDAC subtyping, FGFR-PRS for identifying FGFR inhibitor candidates in urothelial cancer, AF-PRS for NSCLC chemotherapy prognosis, ICI-PRS for immune checkpoint inhibitor response prediction, and rADIO for antigen discovery and immunotherapy biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full GeneCentric Therapeutics company profile →
Sestina Bio
HQ: United States
Website
- Description: Provider of automated synthetic biology platforms and gene-editing tools to sustainably feed, clothe, and treat the world's population, including the GenoScaler™ Platform for automated synthetic biology and the MAD7® Nuclease for precise genome modifications.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sestina Bio company profile →
ViroGates
HQ: Denmark
Website
- Description: Provider of suPARnostic blood test products for better triaging in hospitals, primarily used in emergency departments for risk stratification to improve patient care, reduce healthcare costs, and empower clinical staff.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ViroGates company profile →
Fulcrum Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology therapies targeting rare genetic diseases at their root cause, including losmapimod (a small molecule under investigation for facioscapulohumeral muscular dystrophy) and FTX-6058 (a small molecule designed to increase expression of fetal hemoglobin for treating sickle cell disease and beta-thalassemia).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fulcrum Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Foresight Diagnostics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Foresight Diagnostics
2.2 - Growth funds investing in similar companies to Foresight Diagnostics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Foresight Diagnostics
4.2 - Public trading comparable groups for Foresight Diagnostics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →